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BIATRIAL COX MAZE IV: WE
ARE GOING IN THE RIGHT
DIRECTION
To the Editor:
I read with great interest the article
by Lawrance and colleagues,1 and I
congratulate them on this very
interesting and well-written article.
They have shown that the Cox maze
IV procedure, with its inherent
variations, can be performed bymeans2442 The Journal of Thoracic andof a less invasive right anterolateral
minithoracotomy with excellent
outcome. My personal preference is
for the classic standard ‘‘cut-and-
sew’’ Cox maze III procedure. Once
the surgeon has acquired technical
expertise, this procedure is both easy
and safe to do. What is truly important
is not the complexity of the procedure,
but rather the aortic crossclamp time.
This is the rub, and this is why
alternative energy sources for atrial
fibrillation surgery have mushroomed
in recent years. Since 2002, this
has been termed as Cox maze IV
procedure. Damiano and his working
group2 have been pioneers in this
technology. The idea proposed by
Lawrance and colleagues1 looks
promising. In addition to the mini-
mally invasive surgery, they used the
only 2 energy sources that have been
proved to be successful achieving
full transmural lesions in the atria,
bipolar radiofrequency and cryole-
sion. This great effort by Lawrance
and colleagues1 in this article high-
lights that the trend is now toward
the idea conceived by Cox3 11 years
ago. He stated that surgery for atrial
fibrillation should meet the following
conditions: (1) the procedure should
preferably be epicardial by nature;
(2) the energy source should be
capable of penetrating epicardial fat
and ablating all types of atrial fibrilla-
tion; (3) cardiopulmonary bypass
must be avoided; (4) the procedure
should be amenable to endoscopic or
minimally invasive techniques; (5) it
should be performed in less than 1
hour; and (6) hospital discharge
should be possible on the first
postoperative day. Although it is true
that not all these objectives have
been achieved, we must recognize
that we are on the right track. Novel
devices are being developed4,5; as
yet, however, transmural lesions
have not been safely produced on the
beating heart by epicardial ablation.
Unfortunately, cardiopulmonary by-
pass remains a crucial aspect to
perform this kind of procedure. TheCardiovascular Surgery c November 20most important point is that we are
going on the right direction, each
moment getting closer to the goal. I
really congratulate Lawrance and
colleagues1 for this fine and great
effort.
Ovidio A. Garcia-Villarreal, MD
Department of Cardiac Surgery
Hospital of Cardiology UMAE 34
Instituto Mexicano del Seguro Social
Monterrey, MexicoReferences
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POLYTETRAFLUOROETHY-
LENE NEOCHORDAE USED
FOR MITRALVALVE REPAIR:
DOES SIZE MATTER?
To the Editor:
In a report published in another
journal in 2007,1 we reported 2 cases
of rupture of synthetic chordae tendi-
neae (expanded polytetrafluoroethylene
[ePTFE]).Wealso analyzed thepossible
causes of what was then considered an
extremely rare finding, which had first
been reported by Buttany and14
